Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 100 participants.
Also called NCT07792239
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 100 participants
- Sponsor
- Xyra, LLC
- Registry
-
NCT07792239 -
2025-523860-19-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Poland
- Registry status
- Recruiting
Technical summary
Registry record NCT07792239. Allocation not applicable; no masking; primary purpose treatment. Start 2026-08-06 (actual); primary completion 2027-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dose Escalation Study to Assess Safety, Tolerability, and Efficacy of Budiodarone Treatment With Non-permanent Atrial Fibrillation
- Acronym
- Harbor-AF
- Condition
- Atrial Fibrillation (AF)
- Condition
- Paroxysmal AF
- Intervention (Drug)
- Budiodarone 200 mg BID
- Intervention (Drug)
- Budiodarone 400 mg BID
- Intervention (Drug)
- Budiodarone 600 mg BID
- Intervention (Drug)
- Budiodarone 800 mg BID
- Lead sponsor
- Xyra, LLC
- Collaborator
- Amarex Clinical Research
Record details
- Record id
cardio:ct-nct07792239- Content hash
a50060284e87608c421af22e2fd9656407f18bdb137046f4e70b121ccf62a705